Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer

Harry, Vanessa N.; Semple, Scott; Gilbert, Fiona J.; Parkin, David E.

doi:10.1016/j.ygyno.2008.07.048

Cited by 213 publications

(202 citation statements)

References 37 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…Although there is little published data, DWI seems to be a very promising emerging technique in the evaluation of uterine cervical cancer [8,[22][23][24][25]. Seven ESUR centres routinely use DWI.…”

Section: Diffusion Weighted Imaging (Dwi)mentioning

confidence: 99%

Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology

Balleyguier

Sala

Cunha³

et al. 2010

Eur Radiol

264

199

View full text Add to dashboard Cite

Objective: To design clear guidelines for the staging and follow-up of patients with uterine cervical cancer, and to provide the radiologist with a framework for use in multidisciplinary conferences. Methods: Guidelines for uterine cervical cancer staging and follow-up were defined by the female imaging subcommittee of the ESUR (European Society of Urogenital Radiology) based on the expert consensus of imaging protocols of 11 leading institutions and a critical review of the literature. Results: The results indicated that high field Magnetic Resonance Imaging (MRI) should include at least two T2-weighted sequences in sagittal, axial oblique or coronal oblique

show abstract

Section: Diffusion Weighted Imaging (Dwi)mentioning

confidence: 99%

Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology

Balleyguier

Sala

Cunha³

et al. 2010

Eur Radiol

264

199

View full text Add to dashboard Cite

show abstract

“…Water diffusion in the tissue can be assessed with DW MRI through the ADCs. Low ADCs measured before radiotherapy have been shown to be associated with response to radiotherapy for brain lesions (122), cervical cancer (123), and head and neck cancer (124). Similarly, increases in ADCs measured during radiotherapy in patients with brain (122), cervical (123), liver (125), rectal (126), and head and neck cancer (124) have been shown to be associated with a favorable outcome.…”

Section: Prognostic Role Of Molecular Imaging In Radiation Therapymentioning

confidence: 92%

“…Low ADCs measured before radiotherapy have been shown to be associated with response to radiotherapy for brain lesions (122), cervical cancer (123), and head and neck cancer (124). Similarly, increases in ADCs measured during radiotherapy in patients with brain (122), cervical (123), liver (125), rectal (126), and head and neck cancer (124) have been shown to be associated with a favorable outcome. Obstacles toward more successful use of DCE or DW MRI for treatment response assessment includes the unknown optimal timing of DCE MRI (which is most likely disease-dependent (127)), and the lack of reproducibility in ADCs between vendors and institutions (128).…”

Section: Prognostic Role Of Molecular Imaging In Radiation Therapymentioning

confidence: 92%

Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) how to acquire high-quality molecular images for use in radiation therapy; (2) how molecular imaging can be used to plan radiotherapy and evaluate treatment efficacy; and (3) the limitations and challenges to widespread use of molecular imaging in radiation oncology.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through November 2018.Molecular imaging plays a central role in the management of radiation oncology patients. Specific uses of imaging, particularly to plan radiotherapy and assess its efficacy, require an additional level of reproducibility and image quality beyond what is required for diagnostic imaging. Specific requirements include proper patient preparation, adequate technologist training, careful imaging protocol design, reliable scanner technology, reproducible software algorithms, and reliable data analysis methods. As uncertainty in target definition is arguably the greatest challenge facing radiation oncology, the greatest impact that molecular imaging can have may be in the reduction of interobserver variability in target volume delineation and in providing greater conformity between target volume boundaries and true tumor boundaries. Several automatic and semiautomatic contouring methods based on molecular imaging are available but still need sufficient validation to be widely adopted. Biologically conformal radiotherapy (dose painting) based on molecular imaging-assessed tumor heterogeneity is being investigated, but many challenges remain to fully exploring its potential. Molecular imaging also plays increasingly important roles in both early (during treatment) and late (after treatment) response assessment as both a predictive and a prognostic tool. Because of potentially confounding effects of radiation-induced inflammation, treatment response assessment requires careful interpretation. Although molecular imaging is already strongly embedded in radiotherapy, the path to widespread and all-inclusive use is still long. The lack of solid clinical evidence is the main impediment to broader use. Recommendations for practicing physicians are still rather scarce. 18 F-FDG PET/CT remains the main molecular imaging modality in radiation oncology applications. Although other molecular imaging options (e.g., proliferation imaging) are becoming more common, their widespread use is limited ...

show abstract

“…The rates of adverse reactions in the two groups after the treatment were also compared, and adverse reactions involving bone marrow inhibition, gastrointestinal allergy, cystitis or urethritis were used as observational parameters (Harry, 2008).…”

Section: Observational Parametersmentioning

confidence: 99%

Clinical value of concurrent radiochemotherapy in cervical cancer and comparison of ultrasonography findings before and after radiochemotherapy

Yan

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Herein, we investigated the clinical value of concurrent radiochemotherapy for patients with advanced cervical cancer and its effects on adverse clinical symptoms. Forty patients with cervical cancer were recruited from January 2011 to January 2014 for this study. Participants were randomly allocated into a test or control group, with 20 patients in each group. Patients in the test group were treated with concurrent radiochemotherapy, whereas patients in the control group received only traditional radiotherapy. At the end of the observation period, clinical efficacy in the two groups was compared. Patients were followed up for 2 years, and the rates of recurrence, survival, and complications were compared; ultrasonographic findings before and after radiotherapy were also correlated. Patients in the test group who received concurrent radiochemotherapy showed significantly higher clinical efficacy than the control group at the end of treatment cycles. After 2 years of follow-up, the rates of recurrence, mortality, and complications were all significantly lower in the test group than in the control group (P < 0.05). Comparison of ultrasonographic findings before and after radiochemotherapy showed that the size of the tumor was significantly smaller in patients after concurrent radiochemotherapy. Compared with traditional radiotherapy, concurrent radiochemotherapy significantly improved clinical outcomes in patients with advanced cervical cancer. Concurrent radiochemotherapy also enhanced the rate of survival and decreased the rate of relapse, with enhanced clinical safety and no significant side effects. Thus, concurrent radiochemotherapy can be more broadly applied in the treatment of advanced cervical cancer.

show abstract

Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer

Cited by 213 publications

References 37 publications

Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology

Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology

Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy

Clinical value of concurrent radiochemotherapy in cervical cancer and comparison of ultrasonography findings before and after radiochemotherapy

Contact Info

Product

Resources

About